Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery

References

• Substance Abuse and Mental Health Services Administration. Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863.
   Google Scholar
• Centers for Disease Control. Injury Prevention and Control; Prescription Drug Overdose Data. http://www.cdc.gov/drugoverdose/data/overdose.html. Published 2014. Accessed February 9, 2016.
   Google Scholar
• Han B, Compton WM, Jones CM, Cai R. Nonmedical prescription opioid use and use disorders among adults aged 18 through 64 years in the United States, 2003–2013. JAMA. 2015;314:1468–1478.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM. Controlled substance prescribing patterns—Prescription Behavior Surveillance System, eight states, 2013. MMWR Surveill Summ. 2015;64(SS-9):1–14.
   Web of Science ®Google Scholar
• Berwick D, Bauchner H, Fontanarosa PB. Innovations in health care delivery: call for papers for a yearlong series. JAMA. 2015;314:675–676.
   Web of Science ®Google Scholar
• Holdsworth MT, Benson BE, Dole EJ. Risk-based strategy for outpatient pharmacy practice: focus on opioids. J Am Pharm Assoc. 2015;55: 553–559.
   Google Scholar
• Drug Facts and Comparisons® Publishing Group. Drug Facts and Comparisons®. Philadelphia, PA: Wolters Kluwer Health; 2008.
   Google Scholar
• Goodman AJ, Le Bourdonnec B, Dolle RE. Mu opioid receptor antagonists: recent developments. ChemMedChem. 2007;2:1552–1570.
   PubMed Web of Science ®Google Scholar
• Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36:240–253.
   PubMed Web of Science ®Google Scholar
• Barton ED, Colwell CB, Wolfe T, et al. Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. J Emerg Med. 2005;29:265–271.
   PubMed Web of Science ®Google Scholar
• Robinson A, Wermeling DP. Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm. 2014;71:2129–2135.
   PubMed Web of Science ®Google Scholar
• Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104:2067–2074.
   PubMed Web of Science ®Google Scholar
• Kelly A-M, Kerr D, Dietze P, Patrick I, Walker T, Koutsogiannis Z. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med J Aust. 2005;182:24–27.
   PubMed Web of Science ®Google Scholar
• Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
   PubMed Web of Science ®Google Scholar
• Hammett TM, Phan S, Gaggin J, et al. Pharmacies as providers of expanded health services for people who inject drugs: a review of laws, policies, and barriers in six countries. BMC Health Serv Res. 2014;14:261.
   PubMed Web of Science ®Google Scholar
• Davis CS, Walley AY, Bridger CM. Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J Law Med Ethics. 2015;43(Suppl 1):19–22.
   PubMed Web of Science ®Google Scholar
• Davis CS, Carr D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 2015;157:112–120.
   PubMed Web of Science ®Google Scholar
• Brodrick JE, Brodrick CK, Adinoff B. Legal regimes surrounding naloxone access: considerations for prescribers. Am J Drug Alcohol Abuse. 2016;42(2):117–128.
   Web of Science ®Google Scholar
• R Core Team. R: A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2013.
   Google Scholar
• Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med. 2011;12(Suppl 2):S26–S35.
   PubMed Web of Science ®Google Scholar
• Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012;125:8–18.
   PubMed Web of Science ®Google Scholar
• Frenk SM, Porter KS, Paulozzi LJ. Prescription Opioid Analgesic Use Among Adults: United States, 1999–2012. NCHS Data Brief. 2015;(189):1–8.
   PubMedGoogle Scholar
• Papastergiou J, Folkins C, Li W, Zervas J. Community pharmacist-administered influenza immunization improves patient access to vaccination. Can Pharm J (Ott). 2014;147:359–365.
   PubMedGoogle Scholar
• Saba M, Diep J, Saini B, Dhippayom T. Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy. J Clin Pharm Ther. 2014;39:240–247.
   PubMed Web of Science ®Google Scholar
• Willis A, Rivers P, Gray LJ, Davies M, Khunti K. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PLoS ONE. 2014;9:e91157.
   PubMed Web of Science ®Google Scholar
• Anderson C, Blenkinsopp A, Armstrong M. Feedback from community pharmacy users on the contribution of community pharmacy to improving the public's health: a systematic review of the peer reviewed and non-peer reviewed literature 1990–2002. Health Expect. 2004;7:191–202.
   PubMed Web of Science ®Google Scholar
• Lindsey L, Husband A, Nazar H, Todd A. Promoting the early detection of cancer: a systematic review of community pharmacy-based education and screening interventions. Cancer Epidemiol. 2015;39:673–681.
   PubMed Web of Science ®Google Scholar
• Bleske BE, Dillman NO, Cornelius D, et al. Heart failure assessment at the community pharmacy level: a feasibility pilot study. J Am Pharm Assoc. 2014;54:634–641.
   Google Scholar
• Taitel M, Cohen E, Duncan I, Pegus C. Pharmacists as providers: targeting pneumococcal vaccinations to high risk populations. Vaccine. 2011;29:8073–8076.
   PubMed Web of Science ®Google Scholar
• Ayorinde AA, Porteous T, Sharma P. Screening for major diseases in community pharmacies: a systematic review. Int J Pharm Pract. 2013;21:349–361.
   PubMedGoogle Scholar
• Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf. 2008;17:997–1005.
   PubMed Web of Science ®Google Scholar
• Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict. 2009;18:5–14.
   PubMed Web of Science ®Google Scholar
• Centers For Disease Control and Prevention. Prevention Status Reports 2013: Prescription Drug Overdose—New Mexico. http://www.cdc.gov/psr/prescriptiondrug/2013/nm-pdo.pdf. Published 2014. Accessed November 11, 2015.
   Google Scholar
• Bureau of Vital Records and Health Statistics (BVRHS), New Mexico Department of Health. New Mexico Death Data. https://ibis.health.state.nm.us/community/highlight/profile/DrugOverdoseDth.Cnty/geocnty/39.html. Accessed October 30, 2015.
   Google Scholar
• Nandi A, Galea S, Ahern J, Bucciarelli A, Vlahov D, Tardiff K. What explains the association between neighborhood-level income inequality and the risk of fatal overdose in New York City? Soc Sci Med. 2006;63:662–674.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crimes. Community Based Treatment. https://www.unodc.org/treatment/en/community_based_treatment.html. Accessed October 26, 2015.
   Google Scholar
• Albert S, Brason I, Fred W, et al. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med. 2011;12(Suppl 2):S77–S85.
   PubMed Web of Science ®Google Scholar
• Rose VJ, Lutnick A, Kral AH. Feasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacists. J Psychoactive Drugs. 2014;46:226–232.
   PubMed Web of Science ®Google Scholar
• Zaller ND, Yokell MA, Green TC, Gaggin J, Case P. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse. 2013;48:590–599.
   PubMed Web of Science ®Google Scholar
• Crawford ND, Amesty S, Rivera AV, Harripersaud K, Turner A, Fuller CM. Community impact of pharmacy—randomized intervention to improve access to syringes and services for injection drug users. Health Educ Behav. 2014;41:397–405.
   PubMed Web of Science ®Google Scholar
• Bailey AM, Wermeling DP. Naloxone for opioid overdose prevention pharmacists' role in community-based practice settings. Ann Pharmacother. 2014;48:601–606. doi: 10.1177/1060028014523730.
   PubMed Web of Science ®Google Scholar
• Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2015;28:404–412.
   PubMedGoogle Scholar